[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629756":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":41,"collaborators":10,"id":45,"slug":10,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":10,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":10,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Extension Cohort",null,"Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion",[13],"Other: No intervention",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"No intervention",[9],[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Zhijie Wang, MD","CONTACT","+86 13466323860","jie_969@163.com",[25],{"facility":26,"status":27,"city":28,"state":10,"zip":10,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"National Cancer Center\u002FNational Clinical Research Center for Cancer\u002FCancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","RECRUITING","Beijing","China","CN",{"type":32,"coordinates":33},"Point",[34,35],116.39723,39.9075,{"lat":35,"lon":34},[38],{"name":39,"role":21,"phone":40,"phoneExt":10,"email":23},"Wang Zhijie","+8613466323860",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhijie Wang","Chief Physician","100629756",false,"NCT07478809","A Retrospective Real-World Study Based on RATIONALE-307","Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Patients With Advanced Squamous NSCLC: a Retrospective Real-World Study Based on RATIONALE-307","Inclusion Criteria:\n\n* Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion\n\nExclusion Criteria:\n\n* Patients who had a documented death before study completion in the RATIONALE-307 trial","ALL",{"count":53,"type":54},109,"ESTIMATED","OBSERVATIONAL","The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.",[58],"NSCLC (Advanced Non-small Cell Lung Cancer)","2026-03-23",{"date":61,"type":62},"2026-03-27","ACTUAL",{"date":64,"type":62},"2026-02-28",{"date":66,"type":54},"2027-12-31",{"name":5,"class":6},1]